Table 3.

Characteristics of included studies.

	Patients				Intervention
Studies	Disease	T/C	M/F	Age (years)	Treatment group	Control group	Duration (days)	Outcomes
Hu 2020	Confirmed	142/142	150/134	≥18	LH capsules (4 capsules thrice daily) in combination with usual treatment	usual treatment including oxygen therapy, antiviral medications, and symptomatic therapies	14	O1,O2,O3,O4,O5,
Yu 2020	Confirmed	147/148	171/124	18-75	LH granules (1 packet thrice daily) in combination with usual treatment	usual treatment including abidol (0.2g,tid)+ moxifloxacin (0.4g,qd)+ ambroxol (30 mg,tid)	7	O1, O2, O4,
Lv 2020	Suspected	63/38	46/55	≥18	LH granules (1 packet thrice daily) in combination with usual treatment	usual treatment including nutritional support, symptomatic treatment, antiviral and antibiotic drug treatment	10	O2,O5
Cheng 2020	Confirmed	51/51	53/49	18-70	LH granules (1 packet thrice daily) in combination with usual treatment	usual treatment including nutritional support, symptomatic treatment, antiviral and antibiotic drug treatment	7	O1, O2,O3,O4,
Yao 2020	Confirmed	21/21	28/14	≥18	LH granules (1 packet thrice daily) in combination with usual treatment	usual treatment recommended in the Diagnosis and Treatment Protocol for Coronavirus Pneumonia (Trial version 4)	—	O3